Cefoxitinにかんする基礎的ならびに臨床的研究

DOI Web Site

書誌事項

タイトル別名
  • LABORATORY AND CLINICAL STUDIES ON CEFOXITIN
  • Cefoxitin ニ カンスル キソテキ ナラビニ リンショウテキ ケンキュ

この論文をさがす

抄録

The present paper reports the result obtained in laboratory and clinical studies on cefoxitin (CFX).<BR>1) The peak values of distribution of CFX MIC's were 3.12, 6.25, 12.5 and 6.25μg/ml, respectively, against clinically isolated strains of Staphylococcus aureus, Escherichia coli, Klebsiella and Proteus mirabilis. The antimicrobial activity of CFX seemed to be slightly less than that of CEZ. However, no resistant strains to CFX were observed though a few strains of E. coli, Klebsiella and Pr. mirabilis tested were resistant to CEZ. Most strains of Pr. vulgaris tested were resistant to CEZ but were sensitive to CFX in the range of MICs of 3.12-12.5μg/ml.<BR>2) Cefoxitin was given to 4 patients with infected lung cancer (2), chronic cystitis (1) and septicemia (1) at a daily dose of 2-8g, and the clinical effect obtained was effective in 2, not effective in 1 and not evaluable in 1. Deterioration of renal function in a patient and fever in another were seen as side effects.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ